GlassScriptPhysician profile
Traci L Ivey
NPI 1831157858
$1,757.11
in general payments reported to CMS, 2019-2025
24 companies · $162 in 2025
The $162 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $84.42 · 2020: $76.35 · 2021: $129 · 2022: $230 · 2023: $620 · 2024: $455 · 2025: $162.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,212 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,212.41 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $394.09 | 2022-2024 | Quviviq |
| Lilly USA, LLC | $283.74 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $188.39 | 2019-2024 | |
| Novo Nordisk INC | $146.39 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Currax Pharmaceuticals LLC | $145.45 | 2021-2023 | Onzetra Xsail, Contrave, Nexletol |
| Abbott Laboratories | $117.40 | 2022-2025 | Freestyle Libre 2, Freestyle Libre |
| Astrazeneca Pharmaceuticals LP | $84.68 | 2022-2025 | Airsupra, Farxiga |
| Takeda Pharmaceuticals U.S.A., INC. | $47.89 | 2022-2024 | Trintellix |
| Organogenesis INC. | $45.33 | 2023-2024 | Puraply Am, Puraply |
| Dexcom, INC. | $32.36 | 2023-2025 | Dexcom G6 Transmitter |
| Nestle Healthcare Nutrition INC. | $31.88 | 2023 | |
| Amgen INC. | $28.10 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $25.21 | 2021 | |
| Exact Sciences Corporation | $22.45 | 2023 | Cologuard Collection Kit |
| Seqirus USA INC | $22.37 | 2024 | Fluad, Flucelvax |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $21.80 | 2022 | |
| Sanofi Pasteur INC. | $19.14 | 2025 | |
| Lundbeck LLC | $18.57 | 2022 | |
| Corium, LLC | $17.93 | 2024 | Azstarys |
| Teva Pharmaceuticals USA, INC. | $15.15 | 2023 | Austedo |
| Alfasigma USA, INC. | $14.08 | 2021 | |
| Merck Sharp & Dohme LLC | $11.93 | 2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $11.64 | 2022 | |
| Glaxosmithkline, LLC. | $11.14 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Traci Ivey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.